These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 327909)

  • 1. Serum fibrinogen/fibrin degradation products in patients with ovarian carcinoma.
    Lalos O; Frankendal B; Rudolphi O
    Ann Chir Gynaecol; 1977; 66(3):131-134. PubMed ID: 327909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin degradation products and the diagnosis of ovarian carcinoma.
    Anstey JT; Blythe JG
    Obstet Gynecol; 1978 Nov; 52(5):605-8. PubMed ID: 724180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical significance of thrombin-antithrombin III complex (TAT) and fibrinogen and fibrin degradation products (FDP) levels in ovarian cancer].
    Sawaguchi K; Hojo T; Nozaki S; Yabushita H; Noguchi M; Nakanishi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):73-8. PubMed ID: 1541865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
    J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing ovarian cancer survival after chemotherapy.
    Webb MJ; Malkasian GD; Jorgensen EO
    Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
    [No Abstract]   [Full Text] [Related]  

  • 6. [Determination of fibrinogen-fibrin degradation factors in neoplasms].
    Petrella V; Massara G; Parachini F; Silvera F; Cantone R
    Minerva Med; 1988 Feb; 79(2):117-21. PubMed ID: 3352945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
    Widström O; Kockum C; Nilsson BS
    Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen/fibrin degradation products in serum of patients with idiopathic thrombocytopenic purpura: elevated levels during severe thrombocytopenic phase of the disease.
    Nagasawa T; Kono I; Sakurai T; Kashiwagi H
    Thromb Haemost; 1976 Jun; 35(3):628-34. PubMed ID: 989969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL; Francis CW; Knutson DW; Marder VJ
    J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unreliability of current serum fibrin degradation product (FDP) assays.
    Gaffney PJ; Perry MJ
    Thromb Haemost; 1985 Jun; 53(3):301-2. PubMed ID: 3901388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fibrin fibrinogen degradation products in the urine and blood in patients with diabetes mellitus and renal complications].
    Astrug A; Shipkova P
    Vutr Boles; 1982; 21(5):81-8. PubMed ID: 7164412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
    Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of fibrinolytic activators from human ovarian tumours in organ culture.
    Svanberg L; Astedt B
    Ann Chir Gynaecol; 1976; 65(6):405-7. PubMed ID: 1020906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of serum fibrinogen degradation products (FDP) in the diagnostic and prognostic evaluation of oral cancer.
    Ghosh M; Aroor AR; Raghavan MR
    Ann Dent; 1990; 49(2):11-2, 45. PubMed ID: 2278474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong.
    Chan JC; Kwok MM; Cockram CS; Prematilleke MN; Tomlinson B; Critchley JA
    Singapore Med J; 1993 Apr; 34(2):145-7. PubMed ID: 8266156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer.
    Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Weiss C; Genazzani AR
    Gynecol Oncol; 1997 Jul; 66(1):85-8. PubMed ID: 9234926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of a test for plasma fibrin/fibrinogen degradation products (FDP) based on monoclonal anti-FDP antibody technology: an application for the scoring system of the disseminated intravascular coagulation (DIC) diagnostic criteria].
    Ito K; Wada H; Abe Y; Tomatsu H; Nishioka J; Nobori T
    Rinsho Byori; 2003 Apr; 51(4):295-9. PubMed ID: 12747249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Persistent discrepancy between FDP and D-dimer in a patient with acute leukemia].
    Sato N; Takahashi H; Nikuni K; Seki Y; Wada K; Tatewaki W; Shibata A
    Rinsho Ketsueki; 1995 Mar; 36(3):212-7. PubMed ID: 7783324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid turbidimetric determination of fibrinogen degradation products (FDP).
    Verbruggen HW; Wessels JM
    Thromb Haemost; 1978 Feb; 39(1):12-21. PubMed ID: 580487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.